TelomEye Pharmaceuticals provides treatments to prevent and improve age-related ophthalmologic disorders.
TelomEye Pharmaceuticals has raised $1.0M in total funding. The most recent round was Seed. The last funding was announced in November 2022.
TelomEye Pharmaceuticals's investors include RePie Asset Management, Kerim Kotan, Mehmet Ali Aydinlar.
TelomEye Pharmaceuticals is headquartered in Burlington, Canada.
TelomEye Pharmaceuticals provides treatments to prevent and improve age-related ophthalmologic disorders.
TelomEye Pharmaceuticals is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TelomEye Pharmaceuticals — Funding & Investors." VCBacked, November 17, 2022, https://www.vcbacked.co/company/telomeye-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2022). TelomEye Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/telomeye-pharmaceuticals
{{cite web |title=TelomEye Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/telomeye-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated